Two combination therapies shrink melanoma brain metastases in more than half of patients
Monday, June 5, 2017 - 11:12
in Health & Medicine
A combination regimen of two immunotherapies and another of two targeted therapies each significantly shrank metastatic brain tumors in at least 50 percent of patients in separate multi-center clinical trials, report researchers.